Vanguard Group Inc. Purchases 161,891 Shares of Henry Schein, Inc. (NASDAQ:HSIC)

Vanguard Group Inc. increased its position in Henry Schein, Inc. (NASDAQ:HSIC) by 1.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 15,171,464 shares of the company’s stock after purchasing an additional 161,891 shares during the period. Vanguard Group Inc. owned approximately 11.81% of Henry Schein worth $1,148,632,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of HSIC. JPMorgan Chase & Co. grew its holdings in shares of Henry Schein by 1.1% during the third quarter. JPMorgan Chase & Co. now owns 4,766,305 shares of the company’s stock valued at $353,898,000 after buying an additional 53,506 shares during the last quarter. American Century Companies Inc. boosted its stake in Henry Schein by 7.3% during the 3rd quarter. American Century Companies Inc. now owns 4,719,088 shares of the company’s stock valued at $350,392,000 after purchasing an additional 322,649 shares during the last quarter. Boston Partners increased its holdings in Henry Schein by 144.1% during the 4th quarter. Boston Partners now owns 2,637,429 shares of the company’s stock worth $199,393,000 after purchasing an additional 1,556,831 shares in the last quarter. Fiduciary Management Inc. WI raised its stake in shares of Henry Schein by 17.1% in the fourth quarter. Fiduciary Management Inc. WI now owns 2,284,337 shares of the company’s stock worth $172,947,000 after purchasing an additional 333,855 shares during the last quarter. Finally, Northern Trust Corp lifted its holdings in shares of Henry Schein by 2.8% in the third quarter. Northern Trust Corp now owns 1,647,889 shares of the company’s stock valued at $122,356,000 after purchasing an additional 45,561 shares in the last quarter. Institutional investors and hedge funds own 96.62% of the company’s stock.

Henry Schein Price Performance

Shares of NASDAQ HSIC opened at $66.55 on Friday. The company has a current ratio of 1.75, a quick ratio of 1.02 and a debt-to-equity ratio of 0.47. The stock has a fifty day simple moving average of $70.52 and a two-hundred day simple moving average of $73.11. Henry Schein, Inc. has a 1-year low of $60.01 and a 1-year high of $82.63. The firm has a market cap of $8.52 billion, a price-to-earnings ratio of 22.48, a price-to-earnings-growth ratio of 1.68 and a beta of 0.90.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Tuesday, May 7th. The company reported $1.10 earnings per share for the quarter, topping the consensus estimate of $1.01 by $0.09. Henry Schein had a return on equity of 13.51% and a net margin of 3.12%. The company had revenue of $3.17 billion during the quarter, compared to the consensus estimate of $3.21 billion. During the same quarter in the prior year, the company earned $1.21 EPS. The firm’s quarterly revenue was up 3.7% compared to the same quarter last year. Analysts anticipate that Henry Schein, Inc. will post 5.17 earnings per share for the current year.

Analyst Upgrades and Downgrades

HSIC has been the subject of several recent research reports. Leerink Partnrs reiterated a “market perform” rating on shares of Henry Schein in a report on Monday, February 26th. UBS Group lowered their target price on shares of Henry Schein from $82.00 to $80.00 and set a “neutral” rating for the company in a report on Wednesday, May 8th. TheStreet upgraded shares of Henry Schein from a “c+” rating to a “b-” rating in a report on Monday, February 26th. Piper Sandler increased their price objective on shares of Henry Schein from $78.00 to $86.00 and gave the company an “overweight” rating in a research note on Monday, February 26th. Finally, Evercore ISI lifted their target price on shares of Henry Schein from $79.00 to $83.00 and gave the stock an “in-line” rating in a research report on Wednesday, February 28th. One analyst has rated the stock with a sell rating, six have issued a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, Henry Schein presently has a consensus rating of “Hold” and an average price target of $81.73.

Henry Schein Profile

Henry Schein, Inc provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services.